249 related articles for article (PubMed ID: 21083445)
21. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
22. Azacitidine: in myelodysplastic syndromes.
Siddiqui MA; Scott LJ
Drugs; 2005; 65(13):1781-9; discussion 1790-1. PubMed ID: 16114977
[TBL] [Abstract][Full Text] [Related]
23. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
[TBL] [Abstract][Full Text] [Related]
24. The role of azacitidine in the treatment of myelodysplastic syndromes.
Abdulhaq H; Rossetti JM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1967-75. PubMed ID: 18042004
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
Martin MG; Walgren RA; Procknow E; Uy GL; Stockerl-Goldstein K; Cashen AF; Westervelt P; Abboud CN; Kreisel F; Augustin K; Dipersio JF; Vij R
Am J Hematol; 2009 Sep; 84(9):560-4. PubMed ID: 19650118
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of azacitidine in myelodysplastic syndromes.
Vigil CE; Martin-Santos T; Garcia-Manero G
Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
[TBL] [Abstract][Full Text] [Related]
27. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Fenaux P; Bowen D; Gattermann N; Hellström-Lindberg E; Hofmann WK; Pfeilstöcker M; Sanz G; Santini V
Leuk Res; 2010 Nov; 34(11):1410-6. PubMed ID: 20609474
[TBL] [Abstract][Full Text] [Related]
28. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
29. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
31. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
Fujimaki K; Miyashita K; Kawasaki R; Tomita N
Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
[TBL] [Abstract][Full Text] [Related]
33. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
34. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
35. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
[TBL] [Abstract][Full Text] [Related]
36. Interstitial lung disease associated with azacitidine use: a case report.
Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
[TBL] [Abstract][Full Text] [Related]
37. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
38. Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
Prescrire Int; 2011 Feb; 20(113):40. PubMed ID: 21488589
[TBL] [Abstract][Full Text] [Related]
39. Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Sayar H; Chan RJ; Orschell CM; Chan EM; Yu Z; Hood D; Plett A; Yang Z; Hui CL; Nabinger SC; Kohlbacher KJ; West ES; Walter A; Sampson C; Wu J; Cripe LD
Leuk Res; 2011 Aug; 35(8):1108-10. PubMed ID: 21420732
[TBL] [Abstract][Full Text] [Related]
40. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
Marcucci G; Silverman L; Eller M; Lintz L; Beach CL
J Clin Pharmacol; 2005 May; 45(5):597-602. PubMed ID: 15831784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
